TB 551
Alternative Names: TB-551Latest Information Update: 22 Aug 2024
Price :
$50 *
At a glance
- Originator Twinpig Biolab
- Class Antineoplastics; Peptide drug conjugates
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 22 Aug 2024 Twinpig Biolab anticipates approval of TB 551 for Pancreatic cancer in 2028 (Twinpig Biolab pipeline, August 2024)
- 22 Aug 2024 Twinpig Biolab plans a phase I trial in Pancreatic cancer in 2025 (Twinpig Biolab pipeline, August 2024)
- 22 Aug 2024 Twinpig Biolab plans a phase II trial in Pancreatic cancer in 2026 (Twinpig Biolab pipeline, August 2024)